NasdaqGM - Nasdaq Real Time Price USD
Verrica Pharmaceuticals Inc. (VRCA)
At close: November 5 at 4:00 PM EST
After hours: 7:21 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
13,908.0000
5,124.0000
9,032.0000
12,000.0000
--
Cost of Revenue
2,222.0000
746.0000
725.0000
--
--
Gross Profit
11,686.0000
4,378.0000
8,307.0000
12,000.0000
--
Operating Expense
90,008.0000
67,600.0000
29,603.0000
42,908.0000
40,181.0000
Operating Income
-78,322.0000
-63,222.0000
-21,296.0000
-30,908.0000
-40,181.0000
Net Non Operating Interest Income Expense
-6,044.0000
-1,222.0000
-1,696.0000
-4,172.0000
-2,513.0000
Other Income Expense
--
-2,551.0000
-1,495.0000
--
-1.0000
Pretax Income
-86,933.0000
-66,995.0000
-24,487.0000
-35,080.0000
-42,694.0000
Net Income Common Stockholders
-86,933.0000
-66,995.0000
-24,487.0000
-35,080.0000
-42,694.0000
Diluted NI Available to Com Stockholders
-86,933.0000
-66,995.0000
-24,487.0000
-35,080.0000
-42,694.0000
Basic EPS
-1.89
-1.48
-0.72
-1.30
-1.71
Diluted EPS
-1.89
-1.48
-0.72
-1.30
-1.71
Basic Average Shares
46,349.8780
45,342.4510
34,163.4370
27,044.4620
24,995.5560
Diluted Average Shares
46,349.8780
45,342.4510
34,163.4370
27,044.4620
24,995.5560
Total Operating Income as Reported
-80,859.0000
-65,759.0000
-21,296.0000
-30,908.0000
-40,181.0000
Total Expenses
92,230.0000
68,346.0000
30,328.0000
42,908.0000
40,181.0000
Net Income from Continuing & Discontinued Operation
-86,933.0000
-66,995.0000
-24,487.0000
-35,080.0000
-42,694.0000
Normalized Income
-84,396.0000
-64,458.0000
-23,050.0000
-35,080.0000
-42,694.0000
Interest Income
2,605.0000
2,740.0000
476.0000
123.0000
521.0000
Interest Expense
8,649.0000
3,962.0000
2,172.0000
4,295.0000
3,034.0000
Net Interest Income
-6,044.0000
-1,222.0000
-1,696.0000
-4,172.0000
-2,513.0000
EBIT
-78,284.0000
-63,033.0000
-22,315.0000
-30,785.0000
-39,660.0000
EBITDA
-77,183.0000
-62,197.0000
-21,597.0000
-30,313.0000
-39,431.0000
Reconciled Cost of Revenue
2,222.0000
746.0000
725.0000
--
--
Reconciled Depreciation
1,101.0000
836.0000
718.0000
472.0000
229.0000
Net Income from Continuing Operation Net Minority Interest
-86,933.0000
-66,995.0000
-24,487.0000
-35,080.0000
-42,694.0000
Total Unusual Items Excluding Goodwill
-2,537.0000
-2,537.0000
-1,437.0000
--
--
Total Unusual Items
-2,537.0000
-2,537.0000
-1,437.0000
--
--
Normalized EBITDA
-74,646.0000
-59,660.0000
-20,160.0000
-30,313.0000
-39,431.0000
12/31/2020 - 6/15/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SCPH scPharmaceuticals Inc.
4.0700
+0.99%
TSHA Taysha Gene Therapies, Inc.
1.2700
-5.22%
ANAB AnaptysBio, Inc.
19.88
-0.30%
EPIX ESSA Pharma Inc.
1.7000
+4.29%
PLRX Pliant Therapeutics, Inc.
14.90
+2.83%
ANRO Alto Neuroscience, Inc.
3.7500
+1.08%
ALXO ALX Oncology Holdings Inc.
1.5200
+2.01%
EYPT EyePoint Pharmaceuticals, Inc.
11.61
-0.77%
STRO Sutro Biopharma, Inc.
3.8400
+4.07%
ADVM Adverum Biotechnologies, Inc.
7.72
+2.39%